Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 6—June 2019

Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease

Chad E. Mire, Joan B. Geisbert, Krystle N. Agans, Krista M. Versteeg, Daniel J. Deer, Benjamin A. Satterfield1, Karla A. Fenton, and Thomas W. GeisbertComments to Author 
Author affiliations: Galveston National Laboratory, Galveston, Texas, USA; University of Texas Medical Branch, Galveston

Main Article

Table 1

NiVB Serum neutralization titers in vaccinated African green monkeys (Chlorocebus aethiops)*

Vaccine Animal no. Day −28† Day 0† Day 28†
F only vaccine F-1 <20 640 1,280
F-2 <20 160 2,560

G only vaccine G-1 <20 640 5,120
G-2 <20 640 5,120

F+G vaccine F/G-1 <20 640 2,560
F/G-2 <20 640 5,120
F/G-3 <20 640 2,560

*Titers are reciprocal serum dilution at which 50% of virus was neutralized. NiV, Nipah virus; NiVB, NiV Bangladesh strain.
†Day postchallenge.
‡Terminal day 8 postchallenge.

Main Article

1Current affiliation: Mayo Clinic, Rochester, Minnesota, USA.

Page created: May 20, 2019
Page updated: May 20, 2019
Page reviewed: May 20, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.